KYMR logo

Kymera Therapeutics (KYMR) Cash and cash equivalents

annual cash & cash equivalents:

$120.26M+$10.29M(+9.36%)
December 31, 2024

Summary

  • As of today (July 1, 2025), KYMR annual cash & cash equivalents is $120.26 million, with the most recent change of +$10.29 million (+9.36%) on December 31, 2024.
  • During the last 3 years, KYMR annual cash & cash equivalents has risen by +$72.28 million (+150.66%).
  • KYMR annual cash & cash equivalents is now at all-time high.

Performance

KYMR Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKYMRbalance sheet metrics

quarterly cash & cash equivalents:

$89.97M-$30.29M(-25.19%)
March 31, 2025

Summary

  • As of today (July 1, 2025), KYMR quarterly cash & cash equivalents is $89.97 million, with the most recent change of -$30.29 million (-25.19%) on March 31, 2025.
  • Over the past year, KYMR quarterly cash & cash equivalents has dropped by -$3.54 million (-3.79%).
  • KYMR quarterly cash & cash equivalents is now -42.63% below its all-time high of $156.82 million, reached on September 30, 2021.

Performance

KYMR quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKYMRbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

KYMR Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+9.4%-3.8%
3 y3 years+150.7%+166.7%
5 y5 years+58.2%-

KYMR Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+150.7%-42.2%+79.4%
5 y5-yearat high+287.9%-42.6%+190.2%
alltimeall timeat high+287.9%-42.6%+190.2%

KYMR Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$89.97M(-25.2%)
Dec 2024
$120.26M(+9.4%)
$120.26M(+8.6%)
Sep 2024
-
$110.72M(+63.8%)
Jun 2024
-
$67.61M(-27.7%)
Mar 2024
-
$93.51M(-15.0%)
Dec 2023
$109.97M(+60.8%)
$109.97M(+35.7%)
Sep 2023
-
$81.05M(+54.7%)
Jun 2023
-
$52.39M(+4.5%)
Mar 2023
-
$50.15M(-26.7%)
Dec 2022
$68.39M
$68.39M(-56.1%)
Sep 2022
-
$155.66M(+102.4%)
DateAnnualQuarterly
Jun 2022
-
$76.91M(+128.0%)
Mar 2022
-
$33.73M(-29.7%)
Dec 2021
$47.98M(+54.7%)
$47.98M(-69.4%)
Sep 2021
-
$156.82M(+84.7%)
Jun 2021
-
$84.90M(+59.9%)
Mar 2021
-
$53.10M(+71.3%)
Dec 2020
$31.00M(-59.2%)
$31.00M(-43.2%)
Sep 2020
-
$54.59M(-10.5%)
Jun 2020
-
$60.97M(-19.8%)
Dec 2019
$76.02M(+84.2%)
$76.02M
Dec 2018
$41.26M
-

FAQ

  • What is Kymera Therapeutics annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Kymera Therapeutics?
  • What is Kymera Therapeutics annual cash & cash equivalents year-on-year change?
  • What is Kymera Therapeutics quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Kymera Therapeutics?
  • What is Kymera Therapeutics quarterly cash & cash equivalents year-on-year change?

What is Kymera Therapeutics annual cash & cash equivalents?

The current annual cash & cash equivalents of KYMR is $120.26M

What is the all time high annual cash & cash equivalents for Kymera Therapeutics?

Kymera Therapeutics all-time high annual cash & cash equivalents is $120.26M

What is Kymera Therapeutics annual cash & cash equivalents year-on-year change?

Over the past year, KYMR annual cash & cash equivalents has changed by +$10.29M (+9.36%)

What is Kymera Therapeutics quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of KYMR is $89.97M

What is the all time high quarterly cash & cash equivalents for Kymera Therapeutics?

Kymera Therapeutics all-time high quarterly cash & cash equivalents is $156.82M

What is Kymera Therapeutics quarterly cash & cash equivalents year-on-year change?

Over the past year, KYMR quarterly cash & cash equivalents has changed by -$3.54M (-3.79%)
On this page